T1	Participants 73 131	patients with recurrent or metastatic head and neck cancer
T2	Participants 610 706	patients with recurrent or metastatic SCCHN and no prior systemic therapy for metastatic disease
T3	Participants 1492 1527	patients with oropharyngeal cancers
